Long-term use of vitamin K antagonists and incidence of cancer: a population-based study

Abstract Whether long-term use of vitamin K antagonists (VKAs) might affect the incidence of cancer is a longstanding hypothesis. We conducted a population-based study including all cancer- and thromboembolism-free patients of our health area; study groups were defined according to chronic anticoagulant use to VKA-exposed and control groups. Cancer incidence and cancer-related and overall mortality was assessed in both groups. 76 008 patients (3231 VKA-exposed and 72 777 control subjects) were followed-up for 8.2 (± 3.2) years. After adjusting for age, sex, and time-to-event, the hazard ratio of newly diagnosed cancer in the exposed group was 0.88 (95% confidence interval [95% CI] 0.80-0.98; P < .015). VKA-exposed patients were less likely to develop prostate cancer, 0.69 (95% CI 0.50-0.97; P = .008). The adjusted hazard ratio for cancer-related and overall mortality was 1.07 (95% CI 0.92-1.24) and 1.12 (95% CI 1.05-1.19), respectively. These results support the hypothesis that anticoagulation might have a protective effect on cancer development, especially prostate cancer.

Download Full-text

PCN314 POPULATION BASED STUDY OF BASELINE BONE DENSITY SCREENING IN PROSTATE CANCER PATIENTS TREATED WITH LONG-TERM ANDROGEN DEPRIVATION THERAPY

Value in Health ◽

10.1016/j.jval.2019.09.509 ◽

2019 ◽

Vol 22 ◽

pp. S497

Author(s):

J. Hu ◽

A. Aprikian ◽

M. Vanhuyse ◽

A. Dragomir

Keyword(s):

Prostate Cancer ◽

Bone Density ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Population Based ◽

Androgen Deprivation ◽

Population Based Study

Download Full-text

Bowel, Urinary, and Sexual Problems Among Long-Term Prostate Cancer Survivors: A Population-Based Study

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2008.04.004 ◽

2009 ◽

Vol 73 (1) ◽

pp. 30-38 ◽

Cited By ~ 39

Author(s):

Floortje Mols ◽

Ida J. Korfage ◽

Ad J.J.M. Vingerhoets ◽

Paul J.M. Kil ◽

Jan Willem W. Coebergh ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Survivors ◽

Population Based ◽

Sexual Problems ◽

Population Based Study ◽

Prostate Cancer Survivors

Download Full-text

Long-term oncological outcomes following active surveillance of low risk prostate cancer: A population-based study

European Urology Open Science ◽

10.1016/s2666-1683(20)33884-2 ◽

2020 ◽

Vol 19 ◽

pp. e1907

Author(s):

N. Timilshina ◽

A. Finelli ◽

P. Richard ◽

M. Komisarenko ◽

L. Martin ◽

...

Keyword(s):

Prostate Cancer ◽

Active Surveillance ◽

Population Based ◽

Low Risk ◽

Population Based Study ◽

Oncological Outcomes ◽

Risk Prostate Cancer ◽

Low Risk Prostate Cancer

Download Full-text

Long-term quality of life among localized prostate cancer survivors: Qalipro population-based study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.9594 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 9594-9594

Author(s):

Anne-Valérie Guizard ◽

Clarisse Kerleau ◽

Pascale Grosclaude ◽

Mariette Mercier ◽

Natacha Heutte ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Cancer Survivors ◽

Population Based ◽

Localized Prostate Cancer ◽

Population Based Study ◽

Prostate Cancer Survivors

Download Full-text

Racial differences in long-term prostate cancer specific mortality following conservative management for low-risk prostate cancer: A population-based study.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.7_suppl.121 ◽

2019 ◽

Vol 37 (7_suppl) ◽

pp. 121-121

Author(s):

Grace L. Lu-Yao ◽

Nikita Nikita ◽

Scott W Keith ◽

Joshua Banks ◽

Nathan Handley ◽

...

Keyword(s):

Prostate Cancer ◽

Racial Differences ◽

Population Based ◽

Low Risk ◽

Population Based Study ◽

Specific Mortality ◽

Risk Prostate Cancer ◽

Low Risk Prostate Cancer ◽

Cancer Specific Mortality

121 Background: It is uncertain whether the same criteria for active surveillance can be applied universally across races. This population-based study was undertaken to quantify racial differences in long-term risk of prostate cancer-specific mortality (PCSM) among patients with low-risk prostate cancer (PCa) receiving conservative management. Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database to identify patients who had low-risk PCa (T1-T2a & Gleason 6 & PSA ≤ 10 ng/mL & N0 & M0) diagnosed in 2004 – 2015 and did not receive radical prostatectomy or radiation therapy within one year of diagnosis. Kaplan-Meier analysis was used to calculate PCSM. The Clopper-Pearson method was used to calculate associated 95% confidence intervals. Hazard ratio of PCSM among those with a high PSA (PSA 4-10) compared to those with a low PSA (PSA < 4) was calculated using Cox proportional hazards models adjusted for covariates (including age, race, marital status, insurance status, U.S. region, year of diagnosis, and AJCC clinical tumor stage). Results: Among 33,740 patients with low-risk PCa, long-term PCSM varied with race and PSA levels at diagnosis. For instance, 10-year PCSM was 2.62% (95% CI: 1.15%-5.05%) among African Americans with PSA 4-10 and 0.98% (95% CI:0.16%-3.12%) among Caucasian patients with PSA < 4. There was no significant statistical interaction between race and PSA level on PCSM (p = 0.81). After adjusting for potential confounders, men with PSA 4-10 experienced 2-fold higher PCSM relative to those with PSA < 4 (HR = 1.96, p = 0.011) and African Americans men experienced a 43% higher PCSM compared to Caucasians (HR = 1.43, p = 0.03). Conclusions: Among men diagnosed with low-risk PCa, long-term PCSM varies by race and PSA at diagnosis. More refined risk stratification may improve PCa management among low-risk PCa patients. [Table: see text]

Download Full-text